Integrated Safety Analysis of Filgotinib Treatment for Rheumatoid Arthritis in Patients from Japan Over a Median of 1.5 Years.

Naoki IshiguroYoshiya TanakaTsukasa MatsubaraTatsuya AtsumiKoichi AmanoEiji SugiyamaKunihiro YamaokaKevin WinthropAlan KivitzGerd R BurmesterJacques-Eric GottenbergMark C GenoveseFranziska MatzkiesYing GuoDeyuan JiangBeatrix BartokAlena PechonkinaAkira KondoRobin BesuyenTsutomu Takeuchi

Published in: Modern rheumatology (2022)

Long-term filgotinib treatment (median 1.5, maximum 2.5 years exposure) was well tolerated at 100- and 200-mg doses in Japanese patients with rheumatoid arthritis.

Keyphrases

rheumatoid arthritis
end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
prognostic factors
peritoneal dialysis
replacement therapy
interstitial lung disease
patient reported